The Prasol Chemicals Ltd Date Will Be Updated Soon .
Parasol Chemicals Ltd is one of India’s leading manufacturers of acetone and phosphorous derivatives. The company’s end-users are pharmaceuticals, agrochemicals, home and personal care, and performance chemicals.
Start your investing journey today. How do you open your own demat account for free?
Bidding Dates
Coming Soon
Price Range
₹0 per share
Face Value
₹0 per share
GMP
₹0
Prasol Chemicals Ltd GMP
The Prasol Chemicals Ltd IPO GMP is ₹[].
IPO Overview
Parasol Chemicals is among India’s leading manufacturers of forward-integrated acetone and phosphorous derivatives. The company’s products have end uses in four segments: pharmaceuticals, agrochemicals, home and personal care, and performance chemicals. It is a Government of India certified Two Star Export House Company with a global distribution network spread across 45 countries across Asia, North America and the European Union.
The IPO comprises a fresh issue of equity shares aggregating up to Rs 250 crore and an offer-for-sale (OFS) of up to 90 lakh equity shares by the existing shareholders.
Prasol Chemicals Ltd IPO Financials
| (₹ in millions, except for percentages) | FY21 | FY20 | FY19 |
| Add: Profit before tax | 420.63 | 115.94 | 128.02 |
| Add: Depreciation and amortization expense | 810.53 | 788.37 | 812.62 |
| Finance costs | 202.90 | 261.83 | 227.93 |
| EBITDA | 1,434.06 | 1,166.14 | 1,168.57 |
| Less: Other income | 53.88 | 56.09 | 143.29 |
| Adjusted EBITDA (A) | 1,380.18 | 1,110.05 | 1,025.28 |
| Revenue from operations (B) | 5,100.68 | 4,509.05 | 4,139.86 |
| Adjusted EBITDA Margin (A/B) | 27.06% | 24.62% | 24.77% |
Company Profile
The Parasol Chemicals Limited global network spans nations in Asia, North America, and the European Union. The company is a two-star export house accredited by the Government of India. The brand benefits from its long-standing relationships with customers like PI Industries Limited, Bayer CropScience Limited, Solvay Specialities India Private Limited, Proctor & Gamble, Dr Reddy’s Laboratories Limited, Alembic Pharmaceuticals Limited, Coromandel International Limited, Arkema, Lubrizol India Private Limited, UPL Limited, Olon Active Pharmaceutical Ingredients India Private Limited, MSN Laboratories Private Limited, etc.
More than 35 goods are in the company’s pipeline, and it manufactures over 75 speciality products. t’s EBITDA has decreased by -34.89 % over the previous year. At the same time, it’s book networth has increased by 17.97 %. It offers catalysts, specialty chemicals, organic chemicals, dust suppression systems, and candle filters.
IPO Strenghts
- Experienced promoters and a competent management team.
- Well-established relationships with a loyal customer base.
- Access to markets worldwide, enabling global reach.
IPO Weakness
- Heavy reliance on customers based in the United States.
- Need to adhere to multiple laws and regulations in these countries to ensure compliance.
- Competition from other players in the market.
